Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C
Published 2017. This article is a U.S. Government work and is in the public domain in the USA..
We aimed to determine whether the HCV viral load after four weeks of treatment (W4VL) with direct-acting antiviral agents (DAAs) predicts sustained virologic response (SVR) in a real-world clinical setting. We identified 21 095 patients who initiated DAA-based antiviral treatment in the national Veterans Affairs (VA) healthcare system from 01/01/2014 to 06/30/2015. Week 4 viral load was categorized as undetectable, detectable below quantification (DBQ), detectable above quantification (DAQ) with viral load ≤42 IU/mL and DAQ with viral load >42 IU/mL. Week 4 viral load was undetectable in 36.1%, detectable below quantification in 45.6%, DAQ ≤42 in 9.3%, DAQ >42 in 9.1%. Detectable above quantification was much more common and undetectable week 4 viral load much less common when tested with the Abbott RealTime HCV assay vs the Roche COBAS AmpliPrep/COBAS TaqMan Version 2 assay. Compared to patients with undetectable week 4 viral load (SVR=93.5%), those with detectable below quantification (SVR=91.8%, adjusted odds ratio [AOR] 0.79, P-value=.001), DAQ ≤42 (SVR=90.0%, AOR 0.63, P-value<.001) and DAQ >42 (SVR=86.2%, AOR 0.52, P-value<.001) had progressively lower likelihood of achieving SVR after adjusting for baseline characteristics and treatment duration. Among genotype 1-infected patients who were potentially eligible for 8-week sofosbuvir/ledipasvir monotherapy, we did not find evidence that treatment for 12 weeks instead of 8 weeks was associated with higher SVR, even among those with detectable above quantification. In summary, DBQ and DAQ W4VL are very common in real-world practice, contrary to what was reported in clinical trials, and strongly predict reduced SVR across genotypes and clinically relevant patient subgroups. Whether and how week 4 viral load results should influence treatment decisions requires further study.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Journal of viral hepatitis - 24(2017), 11 vom: 01. Nov., Seite 966-975 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Johnson, K [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 24.05.2018 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/jvh.12731 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM27265650X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM27265650X | ||
003 | DE-627 | ||
005 | 20240316232350.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/jvh.12731 |2 doi | |
028 | 5 | 2 | |a pubmed24n1332.xml |
035 | |a (DE-627)NLM27265650X | ||
035 | |a (NLM)28585416 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Johnson, K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.05.2018 | ||
500 | |a Date Revised 16.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Published 2017. This article is a U.S. Government work and is in the public domain in the USA. | ||
520 | |a We aimed to determine whether the HCV viral load after four weeks of treatment (W4VL) with direct-acting antiviral agents (DAAs) predicts sustained virologic response (SVR) in a real-world clinical setting. We identified 21 095 patients who initiated DAA-based antiviral treatment in the national Veterans Affairs (VA) healthcare system from 01/01/2014 to 06/30/2015. Week 4 viral load was categorized as undetectable, detectable below quantification (DBQ), detectable above quantification (DAQ) with viral load ≤42 IU/mL and DAQ with viral load >42 IU/mL. Week 4 viral load was undetectable in 36.1%, detectable below quantification in 45.6%, DAQ ≤42 in 9.3%, DAQ >42 in 9.1%. Detectable above quantification was much more common and undetectable week 4 viral load much less common when tested with the Abbott RealTime HCV assay vs the Roche COBAS AmpliPrep/COBAS TaqMan Version 2 assay. Compared to patients with undetectable week 4 viral load (SVR=93.5%), those with detectable below quantification (SVR=91.8%, adjusted odds ratio [AOR] 0.79, P-value=.001), DAQ ≤42 (SVR=90.0%, AOR 0.63, P-value<.001) and DAQ >42 (SVR=86.2%, AOR 0.52, P-value<.001) had progressively lower likelihood of achieving SVR after adjusting for baseline characteristics and treatment duration. Among genotype 1-infected patients who were potentially eligible for 8-week sofosbuvir/ledipasvir monotherapy, we did not find evidence that treatment for 12 weeks instead of 8 weeks was associated with higher SVR, even among those with detectable above quantification. In summary, DBQ and DAQ W4VL are very common in real-world practice, contrary to what was reported in clinical trials, and strongly predict reduced SVR across genotypes and clinically relevant patient subgroups. Whether and how week 4 viral load results should influence treatment decisions requires further study | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
650 | 4 | |a ledipasvir | |
650 | 4 | |a response-guided therapy | |
650 | 4 | |a ribavirin | |
650 | 4 | |a sofosbuvir | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a RNA, Viral |2 NLM | |
700 | 1 | |a Green, P K |e verfasserin |4 aut | |
700 | 1 | |a Ioannou, G N |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 24(2017), 11 vom: 01. Nov., Seite 966-975 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2017 |g number:11 |g day:01 |g month:11 |g pages:966-975 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.12731 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2017 |e 11 |b 01 |c 11 |h 966-975 |